Medpace Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Medpace Holdings, Inc. (MEDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $202.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-10
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $202.43M, a 126.69% increase from fiscal 2024.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $89.30M, a 57.92% increase from fiscal 2023.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $56.55M, a 26.81% decline from fiscal 2022.
- Medpace Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $77.26M, a 26.21% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $202.43M 10-K · filed 2026-02-10 | |
| 2024-12-31 | $89.30M 10-K · filed 2026-02-10 | |
| 2023-12-31 | $56.55M 10-K · filed 2026-02-10 | |
| 2022-12-31 | $77.26M 10-K · filed 2025-02-11 | $77.53M 10-K · filed 2023-02-14 |
| 2021-12-31 | $104.69M 10-K · filed 2024-02-13 | |
| 2020-12-31 | $57.93M 10-K · filed 2023-02-14 | |
| 2019-12-31 | $19.81M 10-K · filed 2022-02-15 | |
| 2018-12-31 | $5.33M 10-K · filed 2021-02-16 | |
| 2017-12-31 | $1.62M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |